Viking Therapeutics Inc. (VKTX)
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.
Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024.
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market
Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral rating highlights risks like high entry barriers, competition, and potential need for additional financing, impacting VK2735's commercial viability. Despite strong Phase II data, VK2735 faces competition from innovative obesity treatments, and strategic partnerships or buyouts could be crucial for Viking's success.
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Viking Therapeutics (VKTX -0.99%) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15 to surpass $100 billion later this decade.
Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Last year, Viking Therapeutics (VKTX 1.83%), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February 2024, but, unfortunately, they have been southbound since then.
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Viking Therapeutics (VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.
Viking Therapeutics: No Buyout Needed Now
Viking Therapeutics' hit yearly lows despite strong sector expectations, as it enters pivotal trials for obesity drugs. The biotech announced a production deal with CordenPharma, signaling confidence in FDA approval and eliminating the need for capital-intensive manufacturing facilities. The $150 million prepayment deal with CordenPharma ensures production capacity ensures production capacity for 1 billion oral tablets and billions in annual revenues.
